Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix’s Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana’s Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
Provided By GlobeNewswire
Last update: Apr 9, 2025
Agreement includes the use of Tonix’s TNX-1500, as part of an immunomodulatory regimen to reduce rejection of Makana’s genetically engineered pig organs in xenotransplantation
Read more at globenewswire.comNASDAQ:TNXP (7/22/2025, 2:48:50 PM)
44.1
-1 (-2.22%)
Find more stocks in the Stock Screener
